nach oben

Journal of Clinical Immunology

Erschienen in:

01.05.2010

Immunoglobulin Responsive Chronic Pain

verfasst von: Andreas Goebel

Erschienen in: Journal of Clinical Immunology | Sonderheft 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Over the last 15 years, clinical and experimental data have emerged that suggest that peripheral and central, glial-mediated neuroimmune activation is both necessary and sufficient to sustain chronic pain. Immune modulation appears to be, therefore, a possible new therapeutic option.

Materials and Methods

The Medline database and international trial registry databases were searched using the keywords “intravenous immunoglobulin” or “IVIG,” “pain” or “chronic pain,” “neuropathic pain,” “CRPS,” “complex regional pain syndrome” or "fibromyalgia.”

Results

Evidence from RCTs suggest that IVIG is effective to reduce pain in complex regional pain syndrome (low-dose IVIG) and post-polio syndrome (high-dose IVIG), and open trials have suggested efficacy in additional pain conditions.

Conclusion

IVIG therapy may emerge as a novel treatment modality for refractory cases. However, before this drug can be confidently used by clinicians, important questions need to be answered concerning optimal treatment doses, duration of treatment, and its effect on function and quality of life.

A “noxious” stimulus actually or potentially causes tissue damage.

Macrophages and T-lymphocytes have been shown to later migrate to the perisynaptic space, yet their contribution has not yet been fully defined [8].

The type of the immune activation differs among the various initiating noxious stimuli [9].

Nociceptors are peripheral receptors that sense noxious signals. Sometimes neurons that mainly serve this function are also called nociceptors.

Not all complex pains that develop regionally after trauma qualify for the diagnosis of CRPS. The diagnosis requires the presence of certain autonomic, motor, or skin signs [18].

Neu, in 1983, reported that a single infusion of 10-g IVIG did not improve pain in 7 patients with postherpetic neuralgia [34].

Merskey B. Classification of chronic pain. Seattle: IASP Press; 1994. p. 212.

Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 2000; 9;288(5472):1769–72.

Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 8;196(4286):129–36.

Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287–333. CrossRefPubMed

Phillips C, Main C, Buck R, Aylward M, Wynne-Jones G, Farr A. Prioritising pain in policy making: the need for a whole systems perspective. Health Policy. 2008;88(2–3):166–75. CrossRefPubMed

Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev. 2002;82(4):981–1011. PubMed

DeLeo JA, Tanga FY, Tawfik VL. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist. 2004;10(1):40–52. CrossRefPubMed

Sweitzer SM, Hickey WF, Rutkowski MD, Pahl JL, DeLeo JA. Focal peripheral nerve injury induces leukocyte trafficking into the central nervous system: potential relationship to neuropathic pain. Pain. 2002;100(1–2):163–70. CrossRefPubMed

Colburn RW, Rickman AJ, DeLeo JA. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp Neurol. 1999;157(2):289–304. CrossRefPubMed

10.

Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev. 2006;51(2):240–64. CrossRefPubMed

11.

Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895–926. CrossRefPubMed

12.

Tegeder I, Costigan M, Griffin RS, Abele A, Belfer I, Schmidt H, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med. 2006;12(11):1269–77. CrossRefPubMed

13.

Uçeyler N, Schäfers M, Sommer C. Mode of action of cytokines on nociceptive neurons. Exp Brain Res. 2009;196((1):67–78. CrossRef

14.

Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004; 6;361(1–3):184–7.

15.

Foulkes T, Wood JN. Pain genes. PLoS Genet. 2008;4(7):e1000086. CrossRefPubMed

16.

McCabe CS, Haigh RC, Ring EF, Halligan PW, Wall PD, Blake DR. A controlled pilot study of the utility of mirror visual feedback in the treatment of complex regional pain syndrome (type 1). Rheumatology (Oxford). 2004;42(1):97–101. CrossRef

17.

Moseley GL. Graded motor imagery is effective for long-standing complex regional pain syndrome: a randomised controlled trial. Pain. 2004;108(1–2):192–8. CrossRefPubMed

18.

Harden RN, Bruehl S, Stanton-Hicks M, Wilson PR. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med. 2007;8(4):326–31. CrossRefPubMed

19.

Huygen FJ, De Bruijn AG, De Bruin MT, Groeneweg JG, Klein J, Zijistra FJ. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002;11(1):47–51. CrossRefPubMed

20.

Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology 2001; 26;57(12):2179–84.

21.

Fernandes ES, Schmidhuber SM, Brain SD. Sensory-nerve-derived neuropeptides: possible therapeutic targets. Handb Exp Pharmacol. 2009;(194):393–416.

22.

Munnikes RJ, Muis C, Boersma M, Heijmans-Antonissen C, Zijlstra FJ, Huygen FJ. Intermediate stage complex regional pain syndrome type 1 is unrelated to proinflammatory cytokines. Mediators Inflamm. 2005; 14;2005(6):366–72.

23.

Wieseler-Frank J, Maier SF, Watkins LR. Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. Brain Behav Immun. 2005;19(2):104–11. CrossRefPubMed

24.

de Mos M, Huygen FJ, Dieleman JP, Koopman JS, Stricker BH, Sturkenboom MC. Medical history and the onset of complex regional pain syndrome (CRPS). Pain. 2008;139(2):458–66. CrossRefPubMed

25.

de Mos M, Huygen FJ, van der Hoeven-Borgman M, Dieleman JP, Ch Stricker BH, Sturkenboom MC. Outcome of the complex regional pain syndrome. Clin J Pain. 2009;25(7):590–7. CrossRefPubMed

26.

Goebel A, Vogel H, Caneris O, Bajwa Z, Clover L, Roewer N, et al. Immune responses to Campylobacter and serum autoantibodies in patients with complex regional pain syndrome. J Neuroimmunol. 2005;162(1–2):184–9. CrossRefPubMed

27.

Blaes F, Schmitz K, Tschernatsch M, Kaps M, Krasenbrink I, Hempelmann G, et al. Autoimmune etiology of complex regional pain syndrome (M. Sudeck). Neurology. 2004;63(9):1734–6. PubMed

28.

Kohr D, Tschernatsch M, Schmitz K, Singh P, Kaps M, Schäfer KH, et al. Autoantibodies in complex regional pain syndrome bind to a differentiation-dependent neuronal surface autoantigen. Pain. 2009;143(3):246–51. CrossRefPubMed

29.

Goebel A, Stock M, Deacon R, Sprotte G, Vincent A. Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. Ann Neurol. 2005;57(3):463–4. CrossRefPubMed

30.

Lindenlaub T, Sommer C. Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol. 2003;105(6):593–602. PubMed

31.

Tomaszewski JE, Landis JR, Russack V, Williams TM, Wang LP, Hardy C, et al. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. Urology. 2001;57(6 Suppl 1):67–81. CrossRefPubMed

32.

Genevay S, Finckh A, Payer M, Mezin F, Tessitore E, Gabay C, et al. Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc. Spine (Phila Pa 1976) 2008;1;33(19):2041–6.

33.

Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702. CrossRefPubMed

34.

Neu IS. Behandlung der Zoster-Neuralgie mit polyvalenten 7S-immunoglobulinen. Fortschritte der Medizin. 1983;101:31–2.

35.

Goebel A, Netal S, Schedel R, Sprotte G. Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med. 2002;3(2):119–27. CrossRefPubMed

36.

Goebel A, Baranowski AP, Maurer K, Ghiai A, McCabe C, Ambler G. Intravenous immunoglobulin treatment of complex regional pain syndrome: a randomized, controlled trial. Ann Intern Med. 2010;152(3):152–8. PubMed

37.

Farbu E, Rekand T, Vik-Mo E, Lygren H, Gilhus NE, Aarli JA. Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur J Neurol. 2007;14(1):60–5. CrossRefPubMed

38.

Gonzalez H, Sunnerhagen KS, Sjöberg I, Kaponides G, Olsson T, Borg K. Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol. 2006;5(6):493–500. CrossRefPubMed

39.

Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997;48(2):321–8. PubMed

40.

ClinicalTrials.gov. U.S. National Institutes of Health. http://www.clinicaltrials.gov. Accessed December 18, 2009.

41.

Current Controlled Trials. Springer Science + Business Media. http://www.controlled-trials.com. Accessed December 18, 2009.

42.

Christensen K, Jensen EM, Noer I. The reflex dystrophy syndrome response to treatment with systemic corticosteroids. Acta Chir Scand. 1982;148((8):653–5. PubMed

43.

Munts AG, van der Plas AA, Ferrari MD, Teepe-Twiss IM, Marinus J, van Hilten JJ. Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic complex regional pain syndrome [published online ahead of print Dec. 15, 2009]. Eur J Pain

44.

Caro XJ, Winter EF, Dumas AJ. A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. Rheumatology (Oxford). 2008;47(2):208–11. CrossRef

Titel: Immunoglobulin Responsive Chronic Pain
verfasst von: Andreas Goebel
Publikationsdatum: 01.05.2010
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe Sonderheft 1/2010
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-010-9403-8

Neu im Fachgebiet Innere Medizin

02.06.2023 | Prostatakarzinom | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Immunoglobulin Responsive Chronic Pain

Abstract

Introduction

Materials and Methods

Results

Conclusion

Neu im Fachgebiet Innere Medizin

Erste Rebiopsie der Prostata negativ: ein ziemlich gutes Zeichen

VHF nach Schlaganfall: Wie lange mit dem DOAK warten?

Erfolge mit onkolytischen Viren bei Hirn- und Ovarialtumoren

Länger progressionsfrei durch Dreierkombi mit Cabozantinib

Update Innere Medizin

Springer Medizin

Abstract

Introduction

Materials and Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2010

IVIG Treatment and Prognosis in Guillain–Barré Syndrome

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs

Cell Death Modulation by Intravenous Immunoglobulin

Immunological Origin and Functional Properties of Catalytic Autoantibodies to Amyloid β Peptide

Anti-amyloidogenic Activity of IgGs Contained in Normal Plasma

Neu im Fachgebiet Innere Medizin

Erste Rebiopsie der Prostata negativ: ein ziemlich gutes Zeichen

VHF nach Schlaganfall: Wie lange mit dem DOAK warten?

Erfolge mit onkolytischen Viren bei Hirn- und Ovarialtumoren

Länger progressionsfrei durch Dreierkombi mit Cabozantinib

Update Innere Medizin